Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 5, 2008, Pages 532-537

  Golub, Jonathan E ^a,b,e   Astemborski, Jacquie ^b   Ahmed, Mohammed ^b   Cronin, Wendy ^c   Mehta, Shruti H ^b   Kirk, Gregory D ^a,b   Vlahov, David ^d   Chaisson, Richard E ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^d NEW YORK ACADEMY OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

HIV latent tuberculosis infection; Tuberculosis

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA BASE; DISEASE REGISTRY; DRUG DEPENDENCE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAVENOUS DRUG ABUSE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS; LUNG TUBERCULOSIS; SUBSTANCE ABUSE; TIME;

ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; SUBSTANCE ABUSE, INTRAVENOUS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 62749155009     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31818d5c1c     Document Type: Article

References (27)

1. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119:827-830.
2. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:935-943.
3. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004;1:CD000171.
4. de Pinho AM, Santoro-Lopes G, Harrison LH, et al. Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil. AIDS. 2001;15:2129-2135.
5. Murray CJ, Salomon JA. Modeling the impact of global tuberculosis control strategies. Proc Natl Acad Sci USA. 1998;95:13881-13886.
6. American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005;172:1169-1227.
7. World Health Organization. Interim Policy on Collaborative TB/HW Activities. WHO/HTM/TB/ 2004 330; WHO, Geneva, Switzerland; 2004.
8. World Health Organization/Global Tuberculosis Programme and UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV Policy Statement. Wkly Epidemiol Rec. 1999;74:385-397.
9. Dworkin MS, Adams MR, Cohn DL et al. Factors that complicate the treatment of tuberculosis in HIV-infected patients. JAcquir Immune Defic Syndr. 2005;39:464-470.
10. Riley ED, Vlahov D, Huettner S, et al. Characteristics of injection drug users who utilize tuberculosis services at sites of the Baltimore city needle exchange program. J Urban Health. 2002;79:113-127.
11. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-550.
12. Selwyn PA, Alcabes P, Hartel D, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med. 1992;327:1697-1703.
13. Graham NM, Galai N, Nelson KE, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med. 1996;156:889-894.
14. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-I infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109: 75-100.
15. Graham NM, Nelson KE, Solomon L, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA. 1992;267:369-373.
16. Corbett EL, Charalambous S, Moloi VM, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med. 2004;170:673-679.
17. Daley CL, Small PM, Schecter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231-235.
18. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn. 2006;6:413-422.
19. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-I infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med. 2007;175:514-520.
20. Comstock GW How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847-850.
21. Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119:827-830.
22. Comstock GW, Ferebee SH, Hammes LM. A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis. 1967;95:935-943.
23. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44:94-102.
24. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21: 1441-1448.
25. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002; 359:2059-2064.
26. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19:2109-2116.
27. Girardi E, Sabin CA, d'Arminio Monforte A, et al. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005;41:1772-1782.